Treovir

Executive Summary

Treovir is a private biotech company headquartered in San Diego, CA, focused on developing innovative therapies for brain tumors. Its lead candidate, G207, is a genetically engineered oncolytic herpes simplex virus designed to selectively replicate in and destroy tumor cells while sparing normal tissue. In a Phase 1 clinical trial, G207 demonstrated improved survival in patients with malignant gliomas, with no serious side effects observed—a significant finding given the high unmet need and toxicity of current treatments. These promising results have propelled G207 into Phase 2 development, where it is being evaluated for efficacy in a larger patient population. Treovir's approach aims to change the standard of care for brain tumor patients by offering a therapy that not only extends survival but also maintains quality of life, providing hope to patients with limited options.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout50% success
• H1 2027Potential partnership or licensing deal40% success
• TBDFDA orphan drug or fast track designation update70% success